Tuesday, March 1
Workshop A: Unlocking the Potential of the Complement System: Identifying Novel Avenues for Intervention
8.00 am - 11.00 am
It is clear that inhibiting the complement system could be the key to life-changing therapies for patients with complement-driven renal diseases such as C3 glomerulopathy and aHUS. However, further studies are needed to understand the best therapeutic strategies that could improve prognosis.
Attend this workshop to examine the latest opportunities in identifying complement targeting therapies.
- Interrogating the shared and distinct mechanisms by which complement is activated in
- Delineating which pathways to target for therapeutic intervention
- Analyzing opportunities to use therapeutic complement inhibitors to treat kidney diseases
Vice President &
Head Of Clinical
Workshop B: From Bench to Bedside: Paving the Way for Clinical Success in Lupus Nephritis
11.30 am - 2.30 pm
While lupus nephritis has been an area of significant clinical setbacks for decades, recent progress in drug development to preserve kidney function has been unprecedented. The recent approvals of therapeutics herald a renaissance for lupus nephritis trials, presenting a significant opportunity to build on clinical successes and explore avenues for implementing precision medicine.
Join this workshop to evaluate cutting-edge trial design and opportunities to reduce progression in long-term organ damage.
- Navigating opportunities for precision medicine and personalized treatments in lupus
- Analyzing updates in combination therapies for lupus nephritis
- Regulatory perspective on drug development for lupus: considering acceptable endpoints
Director of the Division
of Rheumatology &
Director, Division of
Chief, Division of
Workshop C: Elucidating the Pathogenesis of IgA Nephropathy & Learning from Clinical Updates to Identify Potential Therapeutic Targets in IgAN
3.00 pm - 6.00 pm
IgA nephropathy is the most common primary glomerulonephritis but remains a significant unmet medical need with no targeted therapies available. Recent translational research has generated greater insight into potential therapeutic targets for this complex autoimmune disease, however, translating findings into clinical practice is challenging.
Get involved in this workshop to keep up to date with the latest in clinical progress in IgAN, and discuss opportunities for future targeted therapies.
- Identifying patients that are most likely to progress to end-stage kidney disease
- Reflecting on recent successes in clinical trials to understand which mechanisms to target
- Analysis of primary endpoints for IgA and obtaining Orphan Drug Designation
The Mayer Professor
of Renal Medicine
University of Leicester